These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31980410)

  • 1. Oncologic Outcomes in Young Adults With Kidney Cancer Treated During the Targeted Therapy Era.
    Sierra PS; Cordeiro MD; Albuquerque EV; Bastos DA; Bonadio RC; Sarkis AS; Cavalcante A; Pontes J; Coelho RF; Nahas WC
    Clin Genitourin Cancer; 2020 Apr; 18(2):e134-e144. PubMed ID: 31980410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK.
    Hawkins R; Fife K; Hurst M; Wang M; Naicker N; Nolasco S; Eisen T; Matakidou A; Gordon J
    BMC Cancer; 2020 Jul; 20(1):670. PubMed ID: 32680483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib.
    Kim MS; Chung HS; Hwang EC; Jung SI; Kwon DD; Hwang JE; Bae WK; Park JY; Jeong CW; Kwak C; Song C; Seo SI; Byun SS; Hong SH; Chung J
    J Korean Med Sci; 2018 Dec; 33(51):e325. PubMed ID: 30546281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
    Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic papillary renal cell carcinoma in the era of targeted therapy - a retrospective study from three European academic centres.
    Stenman M; Staehler M; Szabados B; Sandström P; Laurell A; Lindskog M; Harmenberg U
    Acta Oncol; 2019 Mar; 58(3):306-312. PubMed ID: 30507262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma.
    Chen SH; Xu LY; Wu YP; Ke ZB; Huang P; Lin F; Li XD; Xue XY; Wei Y; Zheng QS; Xu N
    BMC Cancer; 2021 Jan; 21(1):79. PubMed ID: 33468079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
    Kwon T; Lee JL; You D; Jeong IG; Song C; Ahn H; Kim CS; Hong JH
    J Surg Oncol; 2014 Aug; 110(2):145-50. PubMed ID: 24706355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
    Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
    Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy.
    Takagi T; Fukuda H; Kondo T; Ishihara H; Yoshida K; Kobayashi H; Iizuka J; Okumi M; Ishida H; Tanabe K
    Target Oncol; 2019 Apr; 14(2):179-186. PubMed ID: 30927174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive surgical margin following radical nephrectomy is an independent predictor of local recurrence and disease-specific survival.
    Abu-Ghanem Y; Ramon J; Berger R; Kaver I; Fridman E; Leibowitz-Amit R; Dotan ZA
    World J Surg Oncol; 2017 Nov; 15(1):193. PubMed ID: 29096642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
    Xia Y; Liu L; Xiong Y; Bai Q; Wang J; Xi W; Qu Y; Xu J; Guo J
    BMC Cancer; 2017 Jan; 17(1):70. PubMed ID: 28114889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.
    Kang M; Park JY; Jeong CW; Hwang EC; Song C; Hong SH; Kwak C; Chung J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
    J Urol; 2018 Nov; 200(5):989-995. PubMed ID: 29940249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
    Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
    Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
    Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
    JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib.
    Cetin B; Gonul II; Gumusay O; Afsar B; Bilgetekin I; Ozet A; Uner A
    J Cancer Res Ther; 2021; 17(2):408-413. PubMed ID: 34121685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
    Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
    Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.